Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

PartnershipHM17321Positive

AI Analysis

Summary

Hanmi Pharmaceuticals signed an exclusive licensing agreement with Genentech for HM17321, a UCN2 analog for chronic weight management and obesity, with total deal value up to $2.3 billion including upfront payments, milestones, and tiered royalties.

Importance:7/10

Sentiment:

0.80

licensing dealobesityweight managementexclusive partnershipmilestone payments

Read the original article

Published by PR Newswire Biotech on August 24, 2026 5:03 AM

Read Original